Oculis S.A., a clinical-stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic diseases, today announced that a presentation on Phase 2 data from its investigational therapy, OCS-01, in patients with diabetic macular edema (DME) will be made at the Angiogenesis, Exudation, and Degeneration 2020 conference being held on February 8, 2020, in Miami, FL.
"At present, only intravitreal agents are available to treat chronic retinal diseases such as diabetic macular edema," said Riad Sherif, M.D., Chief Executive Officer of Oculis. "A topical treatment option may help serve an unmet need for a non-injectable, effective, safe, adaptable, and readily accessible treatment. OCS-01 is a topically administered dexamethasone/γ-cyclodextrin nanoparticle complex. The Phase 2 trial data to be presented at this conference is the first controlled study of OCS-01 for the treatment of DME."
Details of the presentation
Title: A Phase 2 Study of OCS-01: An Effective Topical Dexamethasone for DME Presenter: Pravin U. Dugel, M.D., Clinical Professor of Ophthalmology Keck School of Medicine University of Southern California Los Angeles, CA Managing Partner, Retinal Consultants of Arizona Retinal Research Institute LLC Phoenix, AZ